JCR Pharmaceuticals Co., Ltd. (JP:4552)
:4552
4552 Stock Chart & Stats
¥712.00
-¥21.00(-3.43%)
At close: 4:00 PM EST
¥712.00
-¥21.00(-3.43%)
Day’s Range― - ―
52-Week Range¥386.00 - ¥824.00
Previous CloseN/A
Volume326.50K
Average Volume (3M)578.69K
Market Cap
¥73.51B
Enterprise Value¥110.89B
Total Cash (Recent Filing)¥13.18B
Total Debt (Recent Filing)¥40.10B
Price to Earnings (P/E)638.6
Beta0.92
Next Earnings
May 07, 2026EPS Estimate
-1.14Next Dividend Ex-DateN/A
Dividend Yield2.71%
Share Statistics
EPS (TTM)0.27
Shares Outstanding129,686,310
10 Day Avg. Volume668,090
30 Day Avg. Volume578,686
Financial Highlights & Ratios
PEG Ratio0.07
Price to Book (P/B)1.27
Price to Sales (P/S)1.81
P/FCF Ratio-3.90
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
¥710.00Price Target Upside-0.28% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)14.28
Revenue Forecast (FY)¥38.57B
Bulls Say, Bears Say
Bulls Say
Niche Biologics & Rare-disease FocusJCR's strategic focus on rare-disease therapies and advanced biologics creates durable product-specific demand, high development barriers, and pricing/reimbursement leverage. Specialized manufacturing and long clinical timelines generate sticky revenue streams and reduce competition over the medium term.
Positive Revenue Growth TrendReported revenue growth of ~7% indicates ongoing commercial traction for marketed products. Sustained top-line expansion supports scale in manufacturing and distribution, enabling reinvestment in R&D and commercialization, which strengthens competitive position over multiple quarters.
Healthy Equity Ratio / Asset BaseA healthy equity ratio and stable equity base provide a balance-sheet buffer against operating volatility and support continued operations while management addresses profitability and cash generation. This structural asset strength aids access to financing and protects long-term operational capacity.
Bears Say
Negative Profitability And MarginsPersistent negative net and operating margins erode retained earnings and limit internal funding for R&D and commercialization. Continued losses weaken pricing flexibility and may force cost-cutting that hurts long-term innovation and market development, impairing durable competitiveness.
Weak Operating And Free Cash FlowNegative operating and free cash flows constrain the company's ability to fund manufacturing, clinical programs, and commercialization from operations. Reliance on external financing increases financing risk and can slow investment in capacity or partnerships critical to long-term growth.
Rising Total DebtAn increasing debt load raises interest and refinancing obligations, reducing financial flexibility and increasing vulnerability if cash generation does not improve. Higher leverage may limit strategic options (M&A, capex) and raise default risk during prolonged earnings weakness.
JCR Pharmaceuticals Co., Ltd. News
4552 FAQ
What was JCR Pharmaceuticals Co., Ltd.’s price range in the past 12 months?
JCR Pharmaceuticals Co., Ltd. lowest stock price was ¥386.00 and its highest was ¥824.00 in the past 12 months.
What is JCR Pharmaceuticals Co., Ltd.’s market cap?
JCR Pharmaceuticals Co., Ltd.’s market cap is ¥73.51B.
When is JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date?
JCR Pharmaceuticals Co., Ltd.’s upcoming earnings report date is May 07, 2026 which is in 35 days.
How were JCR Pharmaceuticals Co., Ltd.’s earnings last quarter?
JCR Pharmaceuticals Co., Ltd. released its earnings results on Jan 28, 2026. The company reported ¥0.27 earnings per share for the quarter, beating the consensus estimate of -¥1.072 by ¥1.342.
Is JCR Pharmaceuticals Co., Ltd. overvalued?
According to Wall Street analysts JCR Pharmaceuticals Co., Ltd.’s price is currently Overvalued.
Does JCR Pharmaceuticals Co., Ltd. pay dividends?
JCR Pharmaceuticals Co., Ltd. pays a Semiannually dividend of ¥10 which represents an annual dividend yield of 2.71%. See more information on JCR Pharmaceuticals Co., Ltd. dividends here
What is JCR Pharmaceuticals Co., Ltd.’s EPS estimate?
JCR Pharmaceuticals Co., Ltd.’s EPS estimate is -1.14.
How many shares outstanding does JCR Pharmaceuticals Co., Ltd. have?
JCR Pharmaceuticals Co., Ltd. has 129,686,310 shares outstanding.
What happened to JCR Pharmaceuticals Co., Ltd.’s price movement after its last earnings report?
JCR Pharmaceuticals Co., Ltd. reported an EPS of ¥0.27 in its last earnings report, beating expectations of -¥1.072. Following the earnings report the stock price went down -2.519%.
Which hedge fund is a major shareholder of JCR Pharmaceuticals Co., Ltd.?
Currently, no hedge funds are holding shares in JP:4552
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
JCR Pharmaceuticals Co., Ltd.
JCR Pharmaceuticals Co., Ltd., a specialty pharmaceuticals company, engages in the research, development, manufacture, import and export, and sale of pharmaceutical products, regenerative medicines, and drug substances in Japan. It offers various therapeutic products, including GROWJECT used for the treatment of growth hormone deficiency and short stature; IZCARGO to treat Mucopolysaccharidosis type II; Agalsidase Beta BS I.V. Infusion used for the treatment of Fabry disease; and TEMCELL HS Inj used to treat acute graft-versus-host disease. The company also develops Epoetin Alfa BS and Darbepoetin Alfa BS Injections for the treatment of renal anemia. In addition, it sells medical devices and laboratory instruments. JCR Pharmaceuticals Co., Ltd. was incorporated in 1975 and is headquartered in Ashiya, Japan.
4552 Stock 12 Month Forecast
Average Price Target
¥710.00
▼(-0.28% Downside)
Technical Analysis
Kyowa Kirin Co
―
Sosei Group
―
Takara Bio Inc.
―
Japan Tissue Engineering Co., Ltd.
―
CellSeed Inc.
―
Options Prices
Currently, No data available
---